Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy
Source abstract
Abstract
Immunotherapy is moving to the frontier of cancer treatment. Drug delivery systems (DDSs) have greatly advanced the development of cancer immunotherapeutic regimen and combination treatment. DDSs can spatiotemporally present tumor antigens, drugs, immunostimulatory molecules, or adjuvants, thus enabling the modulation of immune cells including dendritic cells (DCs) or T-cells directly in vivo and thereby provoking robust antitumor immune responses. Cancer vaccines, immune checkpoint blockade, and adoptive cell transfer have shown promising therapeutic efficiency in clinic, and the incorporation of DDSs may further increase antitumor efficiency while decreasing adverse side effects. This review focuses on the use of nano-, micro-, and macroscale DDSs for co-delivery of different immunostimulatory factors to reprogram the immune system to combat cancer. Regarding to nanoparticle-based DDSs, we emphasize the nanoparticle-based tumor immune environment modulation or as an addition to gene therapy, photodynamic therapy, or photothermal therapy. For microparticle or capsule-based DDSs, an overview of the carrier type, fabrication approach, and co-delivery of tumor vaccines and adjuvants is introduced. Finally, macroscale DDSs including hydrogels and scaffolds are also included and their role in personalized vaccine delivery and adoptive cell transfer therapy are described. Perspective and clinical translation of DDS-based cancer immunotherapy is also discussed. We believe that DDSs hold great potential in advancing the fundamental research and clinical translation of cancer immunotherapy. STATEMENT OF SIGNIFICANCE: Immunotherapy is moving to the frontier of cancer treatment. Drug delivery systems (DDSs) have greatly advanced the development of cancer immunotherapeutic regimen and combination treatment. In this comprehensive review, we focus on the use of nano-, micro-, and macroscale DDSs for the co-delivery of different immunostimulatory factors to reprogram the immune system to combat cancer. We also propose the perspective on the development of next-generation DDS-based cancer immunotherapy. This review indicates that DDSs can augment the antitumor T-cell immunity and hold great potential in advancing the fundamental research and clinical translation of cancer immunotherapy by simultaneously delivering dual or multiple immunostimulatory drugs.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Immunotherapy and Immune Responses · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Cancer immunotherapy10.1126/science.342.6165.1432 ↗
2. An immunogenic personal neoantigen vaccine for patients with melanoma10.1038/nature22991 ↗
3. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer10.1038/nature23003 ↗
4. The blockade of immune checkpoints in cancer immunotherapy10.1038/nrc3239 ↗
5. Monoclonal antibodies: versatile platforms for cancer immunotherapy10.1038/nri2744 ↗
6. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma10.1056/NEJMoa1504030 ↗
7. Nivolumab plus Ipilimumab in advanced melanoma10.1056/NEJMoa1302369 ↗
8. Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed/refractory acute lymphoblastic leukemia10.1182/blood.V128.22.217.217 ↗
9. CAR-T cell therapy: From the bench to the bedside10.3390/cancers9110150 ↗
10. CAR-T cells: the long and winding road to solid tumors10.1038/s41419-018-0278-6 ↗
11. Oncology meets immunology: the cancer-immunity cycle10.1016/j.immuni.2013.07.012 ↗
12. Cancer immunotherapy by dendritic cells10.1016/j.immuni.2008.08.004 ↗
13. Dendritic cells in cancer immunotherapy10.1038/s41563-018-0093-6 ↗
14. Cancer immunotherapy via dendritic cells10.1038/nrc3258 ↗
15. The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy10.1038/nrclinonc.2016.25 ↗
16. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine10.1158/1078-0432.CCR-10-3126 ↗
17. Nanoparticle-based immunotherapy for cancer10.1021/nn5062029 ↗
18. Advancements and challenges in multidomain multicargo delivery vehicles10.1002/adma.201704324 ↗
19. Toward biomaterials for enhancing immune checkpoint blockade therapy
20. Designing hydrogels for controlled drug delivery10.1038/natrevmats.2016.71 ↗
21. Macroscale delivery systems for molecular and cellular payloads10.1038/nmat3758 ↗
22. Fast degradable polycaprolactone for drug delivery10.1021/acs.biomac.8b00266 ↗
23. Small-scale systems for in vivo drug delivery10.1038/nbt876 ↗
24. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent10.1097/00019501-200205000-00008 ↗
25. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up10.1161/01.CIR.0000034447.02535.D5 ↗
26. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome10.1161/01.CIR.0000016042.69606.61 ↗
27. Bridging the gap between macroscale drug delivery systems and nanomedicines: A nanoparticle-assembled thermosensitive hydrogel for peritumoral chemotherapy10.1021/acsami.6b10416 ↗
28. On-demand drug delivery from local depots10.1016/j.jconrel.2015.09.011 ↗
29. Engineered materials for cancer immunotherapy10.1016/j.nantod.2015.06.007 ↗
30. Designing natural and synthetic immune tissues10.1038/s41563-018-0077-6 ↗
31. Material aid for vaccines10.1038/s41563-018-0089-2 ↗
32. Key roles of adjuvants in modern vaccines10.1038/nm.3409 ↗
33. Engineering approaches to immunotherapy10.1126/scitranslmed.3003763 ↗
34. Multi-functional nanocarriers to overcome tumor drug resistance10.1016/j.ctrv.2008.04.003 ↗
35. Guanidinylated cationic nanoparticles as robust protein antigen delivery systems and adjuvants for promoting antigen-specific immune responses in vivo10.1039/C6TB01556E ↗
36. Engineering biodegradable guanidyl-decorated PEG-PCL nanoparticles as robust exogenous activators of DCs and antigen cross-presentation10.1039/C7NR04470D ↗
37. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment10.1126/scitranslmed.3001713 ↗
38. Enrichment and expansion with nanoscale artificial antigen presenting cells for adoptive immunotherapy10.1021/acsnano.5b02829 ↗
39. Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumor-associated macrophages and cancer cells10.1002/adfm.201501283 ↗
40. Polymer nanoparticles for enhanced immune response: Combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells10.1016/j.actbio.2013.12.050 ↗
41. Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses10.1016/j.actbio.2018.08.002 ↗
42. Engineering vaccines and niches for immune modulation10.1016/j.actbio.2013.12.036 ↗
43. Toll-like receptor agonist conjugation: A chemical perspective10.1021/acs.bioconjchem.7b00808 ↗
44. Bioconjugation approaches to produce subunit vaccines composed of protein or peptide antigens and covalently attached toll-like receptor ligands10.1021/acs.bioconjchem.7b00478 ↗
45. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity10.1038/nbt.3371 ↗
46. Structure-based programming of lymph-node targeting in molecular vaccines10.1038/nature12978 ↗
47. Designer vaccine nanodiscs for personalized cancer immunotherapy10.1038/nmat4822 ↗
48. Jain RK. Photodynamic therapy for cancer10.1038/nrc1071 ↗
49. Photodynamic therapy and anti-tumour immunity10.1038/nrc1894 ↗
50. Cancer cell Imaging and photothermal therapy in the near-infrared region by using gold nanorods10.1021/ja057254a ↗
51. Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy10.1021/nl100996u ↗
52. Ultrasmall reduced graphene oxide with high near-infrared absorbance for photothermal therapy10.1021/ja2010175 ↗
53. Biomedical applications of graphene and graphene oxide10.1021/ar300159f ↗
54. Noncovalent functionalization of graphene and gaphene oxide for energy materials, biosensing, catalytic, and biomedical applications10.1021/acs.chemrev.5b00620 ↗
55. Synergistic effect of chemo-photothermal therapy using PEGylated graphene oxide10.1016/j.biomaterials.2011.07.071 ↗
56. Graphene and graphene oxide as new nanocarriers for drug delivery applications10.1016/j.actbio.2013.08.016 ↗
57. Graphene-based smart platforms for combined cancer therapy
58. Immunostimulatory oligonucleotides-loaded cationic graphene oxide with photothermally enhanced immunogenicity for photothermal/immune cancer therapy10.1016/j.biomaterials.2014.08.036 ↗
59. Immune parameters affecting the efficacy of chemotherapeutic regimens10.1038/nrclinonc.2010.223 ↗
60. Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system10.1038/nm.2652 ↗
61. Doxorubicin hydrochloride loaded zymosan-polyethylenimine biopolymeric nanoparticles for dual ‘chemoimmunotherapeutic’ intervention in breast cancer10.1007/s11095-017-2195-2 ↗
62. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy10.1016/j.actbio.2017.11.010 ↗
63. Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles10.1016/j.biomaterials.2012.04.029 ↗
64. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles10.1038/nm.2198 ↗
65. Sequentially responsive therapeutic peptide assembling nanoparticles for dual-targeted cancer immunotherapy10.1021/acs.nanolett.8b01071 ↗
66. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy10.1038/nmat3355 ↗
67. Inflammation-triggered cancer immunotherapy by programmed delivery of CpG and anti-PD1 antibody10.1002/adma.201506312 ↗
68. Nanoparticles target distinct dendritic cell populations according to their size10.1002/eji.200737984 ↗
69. Particulate vaccines: on the quest for optimal delivery and immune response10.1016/j.drudis.2011.04.006 ↗
70. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses10.1586/erv.10.89 ↗
71. The long-term potential of biodegradable poly(lactideco-glycolide) microparticles as the next-generation vaccine adjuvant10.1586/erv.11.126 ↗
72. Shedding light on the cell biology of extracellular vesicles10.1038/nrm.2017.125 ↗
73. Extracellular vesicles: Unique intercellular delivery vehicles10.1016/j.tcb.2016.11.003 ↗
74. Membrane vesicles as conveyors of immune responses10.1038/nri2567 ↗
75. The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy10.1002/ijc.30672 ↗
76. Extracellular vesicles in cancer-implications for future improvements in cancer care
77. Cell-free tumor microparticle vaccines stimulate dendritic cells via cGAS/STING signaling10.1158/2326-6066.CIR-14-0177 ↗
78. Tumor cell-derived microparticles polarize M2 tumor-associated macrophages for tumor progression10.1080/2162402X.2015.1118599 ↗
79. Microparticles produced by human papillomavirus type 16 E7-expressing cells impair antigen presenting cell function and the cytotoxic T cell response10.1038/s41598-018-20779-2 ↗
80. MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity10.1016/j.vaccine.2010.10.040 ↗
81. Efficient delivery of antigen to DCs using yeast-derived microparticles10.1038/srep10687 ↗
82. Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine10.2217/imt-2017-0114 ↗
83. PLGA-based nanoparticles: An overview of biomedical applications10.1016/j.jconrel.2012.01.043 ↗
84. Biodegradation and biocompatibility of PLA and PLGA microspheres10.1016/S0169-409X(97)00048-3 ↗
85. Antigen delivery by lipid-enveloped PLGA microparticle vaccines mediated by in situ vesicle shedding10.1021/bm500337r ↗
86. Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 1110.1016/j.cellimm.2011.04.005 ↗
87. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation10.1016/j.biomaterials.2014.05.067 ↗
88. A therapeutic microparticle-based tumor lysate vaccine reduces spontaneous metastases in murine breast cancer10.1208/s12248-014-9662-z ↗
89. Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice10.1016/j.jconrel.2012.06.015 ↗
90. The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma10.1016/j.biomaterials.2014.03.039 ↗
91. Immunogenic cell death in cancer and infectious disease10.1038/nri.2016.107 ↗
92. Immunogenic cell death amplified by co-localized adjuvant delivery for cancer immunotherapy10.1021/acs.nanolett.7b03218 ↗
93. Three steps to breaking immune tolerance to lymphoma: a microparticle approach10.1158/2326-6066.CIR-14-0173 ↗
94. Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer10.1016/j.biomaterials.2015.04.043 ↗
95. Targeted antigen delivery to dendritic cell via functionalized alginate nanoparticles for cancer immunotherapy10.1016/j.jconrel.2017.04.020 ↗
96. NO prodrug-conjugated, self-assembled, pH-responsive and galactose receptor targeted nanoparticles for co-delivery of nitric oxide and doxorubicin10.1039/C7NR08176F ↗
97. Improving the oral delivery efficiency of anticancer drugs by chitosan coated polycaprolactone-grafted hyaluronic acid nanoparticles10.1039/C4TB00273C ↗
98. Recent advances on chitosan-based micro- and nanoparticles in drug delivery10.1016/j.jconrel.2004.08.010 ↗
99. Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells10.1007/s00262-010-0888-z ↗
100. Cytokine secreting microparticles engineer the fate and the effector functions of T-cells10.1002/adma.201703178 ↗